Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2007 | 2 | 1 | 1-11

Article title

Immunohistochemical determination and grading of CerbB-2 expression in breast cancer: correlation with interpectoral, apical nodal involvement and other prognostic factors


Title variants

Languages of publication



We aimed to investigate the correlation between quantitative CerbB-2 expressions with conventional prognostic factors, and distinct nodal involvement in patients with invasive breast carcinoma. One hundred fifty seven consecutive breast carcinoma patients were retrospectively analysed. Level I–II, Level III, and Rotter (Interpectoral) group lymph nodes were separately examined and recorded. For each patient estrogen receptor (ER), progesteron receptor (PR), CerbB-2, P53 status were defined using immunohistochemistry. Age, tumor localisation, menopausal status, grade and the presence of intraductal component were also recorded. CerbB-2 expression did not correlate with age, localisation and menopausal status. There was a reverse, but weak correlation with tumor size and CerbB-2 expression (p=0.034). In subgroup analysis of CerbB-2 positive cases, the magnitude of CerbB-2 positivity did not correlate with tumor size (p=0.551). In univariate analysis CerbB-2 expression did not correlate with nodal involvement in Level I-II, and Rotter. In subgroup analysis of patients with positive CerbB-2, positivity of CerbB-2 linearly increased with the number of positive lymph nodes in Level I-II, and this difference was significant (p=0,039). There was a significant correlation between CerbB-2 expression and Level III nodal metastases (p=0.005). But this correlation was not significant among CerbB-2 positive patients (p=0.82). P53, PR positivity and the presence of intraductal component did not differ according to oncogene expression. We detected a reverse correlation with ER positivity and CerbB-2 positivity (p=0.011). It is concluded that quantitative expression of CerbB2 positivity increases with nodal involvement in Level I–II axillary lymph nodes, and ER. Also, CerbB-2 positivity is more common among patients with Level III lymph node metastases.










Physical description


1 - 3 - 2007
1 - 3 - 2007


  • Faculty of Medicine Department of General Surgery, Gaziosmanpasa University, Tokat, Turkey
  • Department of Pathology, Ankara Oncology Hospital, Ankara, Turkey
  • Faculty of Medicine Department of Biostatistics, Gaziosmanpasa University, Tokat, Turkey
  • Department of General Surgery, Ankara Oncology Hospital, Ankara, Turkey
  • Department of General Surgery, Ankara Oncology Hospital, Ankara, Turkey
  • Department of Pathology, Ankara Oncology Hospital, Ankara, Turkey
  • Department of General Surgery, Ankara Oncology Hospital, Ankara, Turkey


  • [1] R.T. Greenlee, T. Murray, S. Bolden and P.A. Wingo: “Cancer Statistics”, CA Cancer. J. Clin., Vol. 50, (2000), pp. 7–33. [Crossref]
  • [2] D.L. Page: “Prognosis and breast cancer: recognition of lethal and favourable prognostic types”, Am. J. Surg. Pathol., Vol. 15, (1991), pp. 334–349. http://dx.doi.org/10.1097/00000478-199104000-00002[Crossref]
  • [3] N.J. Bundred: “Prognostic and predictive factors in breast cancer”, Cancer. Treat. Rev., Vol. 27, (2001), pp. 137–142. http://dx.doi.org/10.1053/ctrv.2000.0207[Crossref]
  • [4] E. Tzahar and Y. Yarden: “The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands”, Biochim. Biophys. Acta., Vol. 1377, (1998), pp. 25–37.
  • [5] D.F. Hayes and A.D. Thor: “C-erbB-2 in breast cancer: Development of a clinically useful marker”, Semin. Oncol., Vol. 29, (2002), pp. 231–245. http://dx.doi.org/10.1053/sonc.2002.32899[Crossref]
  • [6] Y. Yarden: “Biology of HER2 and its importance in breast cancer”, Oncology, Vol. 61, (2001), pp. 1–13. http://dx.doi.org/10.1159/000055396[Crossref]
  • [7] C. Isaacs, V. Stearns and D.F. Hayes: “New prognostic factors for breast cancer recurrence”, Semin. Oncol., Vol. 28, (2001), pp. 53–67. http://dx.doi.org/10.1016/S0093-7754(01)90045-4[Crossref]
  • [8] J.S. Huston and A.J. George: “Engineered antibodies take center stage”, Hum. Antibodies., Vol. 10 (2001), pp. 127–142.
  • [9] D J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton: “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2”, N. Engl. J. Med., Vol. 344, (2001), pp. 783–792. http://dx.doi.org/10.1056/NEJM200103153441101[Crossref]
  • [10] D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire: “Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene”, Science., Vol. 235, (1987), pp. 177–182. http://dx.doi.org/10.1126/science.3798106[Crossref]
  • [11] O. Stal, S. Sullivan, S. Wingren, L. Skoog, L.E. Rutqvist, J.M. Carstensen and B. Nordenskjold: “CerbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer”, Eur. J. Cancer., Vol. 31, (1995), pp. 2185–2190. http://dx.doi.org/10.1016/0959-8049(95)00344-4[Crossref]
  • [12] S. Kaptain, L.K. Tan and B. Chen: “HER2/neu and breast cancer”, Diagn. Mol. Pathol., Vol. 10, (2001), pp. 139–152. http://dx.doi.org/10.1097/00019606-200109000-00001
  • [13] A. Tervahauta, M. Eskelinen, S. Syrjanen, P. Lipponen, P. Pajarinen and K. Syrjanen: “Immunohistochemical demonstration of CerbB-2 oncoprotein expression in female breast cancer and its prognostic significance”, Anticancer. Res., Vol. 11, (1991), pp. 1677–1681.
  • [14] F. Rilke, M.I. Colgagni, N. Cascinelli, S. Andreola, M.T. Baldini, R. Bufalino, G. Della Porta, S. Menard, M.A. Pierotti and A. Testori: “Prognostic significance of HER2/neu expression in breast cancer and its relationship to other prognostic factors”, Int. J. Cancer., Vol. 49, (1991), pp. 44–49.
  • [15] S. Tsutsui, S. Ohno, S. Murakami, Y. Hachitanda and S. Oda: “Prognostic value of CerbB-2 expression in breast cancer”, J. Surg. Oncol., Vol. 79, (2002), pp. 216–223. http://dx.doi.org/10.1002/jso.10079[Crossref]
  • [16] A. Borg, B. Baldetrop, M. Ferno, D. Killander, H. Olsson and H. Sigurdsson: “ERBB2 amplification in breast cancer with high rate of proliferation”, Oncogene., Vol. 6, (1991), pp. 137–143.
  • [17] H. Schimmelpenning, E.T. Eriksson, U.G. Falkmer, L.E. Rutqvist, H. Johansson, A. Fallenius and G.U. Auer: “Prognostic significance of immunohistochemical CerbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer”, Eur. J. Surg. Oncol., Vol. 18, (1992), pp. 530–537.
  • [18] S.E. Singletary, C. Allred, P. Ashley, L.W. Bassett, D. Berry, K.I. Bland, P.I. Borgen, G.M. Clark, S.B. Edge, D.F. Hayes, L.L. Hughes, R.V. Hutter, M. Morrow, D.L. Page, A. Recht, R.L. Theriault, A. Thor, D.L. Weaver, H.S. Wieand and F.L. Greene: “Staging System for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manuel”, Surg. Clin. North. Am., Vol. 83, (2003), pp. 803–819. http://dx.doi.org/10.1016/S0039-6109(03)00034-3[Crossref]
  • [19] L.A. Newman, H.M. Kuerer, B. Fornage, N. Mirza, K.K. Hunt, M.I. Ross, F.C. Ames, A.U. Buzdar and S.E. Singletary: “Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer”, Am. J. Surg., Vol. 181, (2001), pp. 313–318. http://dx.doi.org/10.1016/S0002-9610(01)00588-8[Crossref]
  • [20] I.K. Komenaka, V.P. Bauer, F.R. Schnabel, K.A. Joseph, E. Horowitz, B.A. Ditkoff and M.B. El-Tamer: “Interpectoral nodes as the initial site of recurrence in breast cancer”, Arch. Surg., Vol. 139, (2004), pp. 175–178. http://dx.doi.org/10.1001/archsurg.139.2.175[Crossref]
  • [21] S.H. Estourgie, O.E. Nieweg, R.A. Olmos, E.J. Rutgers and B.B. Kroon: “Lymphatic drainage patterns from the breast”, Ann. Surg., Vol. 239, (2004), pp. 232–237. http://dx.doi.org/10.1097/01.sla.0000109156.26378.90[Crossref]
  • [22] D. Marx, A. Schauer, C. Reiche, A. May, L. Ummenhofer, A. Reles, H. Rauschecker, R. Sauer and M. Schumacher: “CerbB-2 expression in correlation to other biological parameters of breast cancer”, J. Cancer. Res. Clin. Oncol., Vol. 116, (1990), pp. 15–20. http://dx.doi.org/10.1007/BF01612634[Crossref]
  • [23] A. Jukkola, R. Bloigu, Y. Soini, E.R. Savolainen, K. Holli and G. Blanco: “CerbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease”, Eur. J. Cancer., Vol. 37, (2001), pp. 347–354. http://dx.doi.org/10.1016/S0959-8049(00)00395-6[Crossref]
  • [24] S. Sjögren, M. Inganas, A. Lindgren, L. Holmberg and J. Bergh: “Prognostic and predictive value of CerbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers”, J. Clin. Oncol., Vol. 16, (1998), pp. 462–469.
  • [25] M. Bebenek, J.K. Bar, A. Harlonzinska and P. Sedlaczek: “Prospective studies of P53 and CerbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement”, Anticancer. Res., Vol. 18, (1998), pp. 619–623.
  • [26] M. Samur, S. Karaveli, H. Bozcuk, E. Pestereli, M. Ozdogan, M. Yildiz, M. Artac and B. Savas: “A novel method of reporting CerbB-2 overexpression: Correlation with grade but not with other prognostic parameters in breast cancer”, Turkish. J. Med. Sci. 2003, Vol. 33, pp. 363–368.
  • [27] A. Barbati, E.V. Cosmi, A. Sidoni, P. Collini, M.G. Porpora, I. Ferri, M. Luthy, V. Lauro and E. Bucciarelli: “Value of CerbB-2 and P53 oncoprotein co-overexpression in human breast cancer”, Anticancer. Res., Vol. 17, (1997), pp. 401–405.
  • [28] M. Saceda, T.W. Grunt, R. Colomer, M.E. Lippman, R. Lupu and M.B. Martin: “Regulation of estrogen receptor concentration and activity by an Erb/HER ligand in breast carcinoma cell lines”, Endocrinol., Vol. 137, (1996), pp. 4322–4330. http://dx.doi.org/10.1210/en.137.10.4322[Crossref]
  • [29] S.A. Fuqua, S.D. Fitzgerald, D.C. Allred, R.M. Elledge, Z. Nawaz, D.P. McDonnell, B.W. O’Malley, G.L. Greene and W.L. McGuire: “Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors”, Cancer. Res., Vol. 52, (1992) pp. 483–486.
  • [30] P.P. Rosen, M.L. Lesser, C.D. Arroyo, M. Cranor, P. Borgen and L. Norton: “Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis”, Cancer., Vol. 75, (1995), pp. 1320–1326. http://dx.doi.org/10.1002/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C[Crossref]
  • [31] H.J. Lipponen, S. Aaltomaa, S. Syrjanen and K. Syrjanen: “CerbB-2 oncogene related to P53 expression, cell proliferation and prognosis in breast cancer”, Anticancer. Res., Vol. 13, (1993), pp. 1147–1152.
  • [32] S.W. Beenken, W.E. Grizzle, R.D. Crowe, M.G. Conner, H.L. Weiss, M.T. Sellers, H. Krontiras, M.M. Urist and K.I. Bland: “Molecular biomarkers for breast cancer prognosis: co-expression of CerbB-2 and P53”, Ann. Surg., Vol. 233, (2001), pp. 630–638. http://dx.doi.org/10.1097/00000658-200105000-00006[Crossref]
  • [33] L.L. Nakopoulou, A. Alexiadou, G.E. Theodoropoulos, A.C. Lazaris, A. Tzonou and A. Keramopoulos: “Prognostic significance of the co-expression of P53 and CerbB-2 proteins in breast cancer”, J. Pathol., Vol. 179, (1996), pp. 31–38. http://dx.doi.org/10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O[Crossref]
  • [34] J. Jacquemier, F. Penault-Llorca, P. Viens, G. Houvenaeghel, J. Hassoun, M. Torrente, J. Adelaide and D. Birnbaum: “Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression”, Anticancer. Res., Vol. 14, (1994), pp. 2773–2778.
  • [35] S. Menard, P. Casalini, S. Pilotti, N. Cascinelli, F. Rilke and M.I. Colnaghi: “No additive impact on patient survival of the double alteration of P53 and CerbB-2 in breast carcinomas”, J. Natl. Cancer. Inst., Vol. 88, (1996), pp. 1002–1003. http://dx.doi.org/10.1093/jnci/88.14.1002[Crossref]
  • [36] C. Lohrisch and M. Piccart: “An overview of HER”, Semin. Oncol., Vol. 28, (2001), pp. 3–11. http://dx.doi.org/10.1016/S0093-7754(01)90103-4[Crossref]
  • [37] X. Jing, K. Kakudo, M. Murakami, Y. Nakamura, M. Nakamura, T. Yokoi, Q. Yang, S. Oura and T. Sakurai: “Intraductal spread of invasive breast carcinoma has a positive correlation with CerbB-2 overexpression and vascular invasion”, Cancer., Vol. 86, (1999), pp. 439–448. http://dx.doi.org/10.1002/(SICI)1097-0142(19990801)86:3<439::AID-CNCR12>3.0.CO;2-U[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.